Business Wire

Allegro DVT Launches the World’s First Hardware-Based VVC/H.266 Decoder Silicon IP

Share

Allegro DVT, the leading provider of video processing silicon IPs, today announced the immediate availability of its AL-D320 video decoder semiconductor IP core supporting the latest Versatile Video Coding (VVC/H.266) format. The AL-D320 core is the world’s first hardware IP to support the new VVC format with 8, 10 and 12-bit samples, chroma sampling of 4:2:0 and 4:2:2 and image resolutions and rates of up to 8K120. Added to this, the core continues to support H.264 and HEVC up to 12-bit and 4:4:4 chroma subsampling.

The Versatile Video Coding (VVC/H.266) format has been developed as the successor to the High Efficiency Video Coding (HEVC/H.265) format, with the aim of 30-50% better video compression for the same perceptual video quality. VVC supports resolutions up to 16K as well as 360° videos.

Nouar Hamze, CEO of Allegro DVT commented “The increased complexity of VVC requires HW based implementations for the decoding function to achieve the best trade-off between power consumption, performance and total cost of the solution.”

He added “The increase in complexity of leading-edge video codecs has lengthened development time. We have developed and released our VVC decoder IP early on to accelerate market adoption. Our release pre-empts the demand in a way that we believe will enable OEMs and semiconductor vendors to confidently move forward with the introduction of solutions with VVC decoding capability and therefore speed up the adoption of this new codec to unlock new use cases such as 8K broadcast worldwide.”

The AL-D320 employs a unique multi-format and multi-core architecture which allows scalability to seamlessly support additional video codecs such as AV1/VP9/HEVC/H.264 and higher decoding throughputs up to 8K60 and 8K120.
The release of this range of VVC decoder IP cores shows a continuation in Allegro DVT’s ability to consistently innovate and deliver at the highest level in the market. Building on existing production-proven video decoder semiconductor IP cores, the AL-D320 range of decoders provides end customers both early access to the latest technology while at the same time minimizing adoption risk.

AL-D320 decoder IP is immediately available for integration by SoC vendors in various technology nodes ranging from 28nm down to 5nm and below through a seamless and proven HW and SW integration kit.

About Allegro DVT

For more information: https://www.allegrodvt.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Elodie Soufi
marcom@allegrodvt.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s Analytics Earns #2 Overall Ranking in Chartis Research STORM505.8.2021 16:15:00 CEST | Press release

Moody’s Analytics is #2 in the inaugural Chartis Research STORM50 (Statistical Techniques, Optimization frameworks and Risk Models) ranking of the world’s leading providers of quantitative solutions for the financial industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005744/en/ Chartis’ STORM50 ranking measures the strength of solutions in quantitative modeling and software, assessing the level of innovation and the quality of the underlying computational infrastructure. The scoring is based on five criteria: breadth and coverage, impact, computational infrastructure, innovation, and strategy. In addition to the #2 ranking overall, Moody’s Analytics placed first in 14 of 55 categories, including Breadth & Coverage, Impact, Strategy, and Innovation, evidencing the depth of the company’s modeling expertise. “The inaugural Chartis Research STORM50 ranking highlights our ability to deliver an integrated view of risk

Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine5.8.2021 15:30:00 CEST | Press release

Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples. Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneous

Andersen Global Strengthens Puerto Rican Coverage with Tax and Advisory Firm5.8.2021 15:30:00 CEST | Press release

Andersen Global adds dimension to its platform in Puerto Rico with the addition of collaborating firm AFS CPA Group LLC (AFS), solidifying its presence in the country with tax and legal coverage. AFS provides tax and advisory services to clients including individuals and small and large businesses, serving a variety of industries such as legal, medical, food and restaurants, apparel, marketing, technology, non-profit and homeowners associations. The firm, established in 2000 by Founder and Managing Partner Antonio Sécola, is based in Gurabo and offers tax, financial, investment and cash management services as well as outsourcing and payroll functions. “As an Arthur Andersen alumnus, I look forward to rejoining the culture and working with like-minded individuals who are committed to serving clients best-in-class solutions,” Antonio said. “Our firm is dedicated to providing the highest quality service, and this collaboration further supplements our ability to deliver seamless solutions

Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine5.8.2021 15:22:00 CEST | Press release

Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine. The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines. The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can c

Loop Energy Enters Joint Market Development Agreement With Técnicas Reunidas to Accelerate the Commercialization of Hydrogen-Powered Vehicles5.8.2021 14:00:00 CEST | Press release

Loop Energy (TSX:LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, announces their joint market development agreement with Técnicas Reunidas (TR) – a global provider of services for investors in hydrogen infrastructure based in Madrid, Spain. Under this agreement, both parties will aim to secure future opportunities that require both TR’s hydrogen know-how and Loop Energy’s fuel cell technology. The initial scope of this joint market agreement focuses on providing hydrogen-based solutions to several key vertical markets: transport agencies, truck, transit and coach bus service fleets, materials handling, warehouse and port logistics including drayage, urban delivery services and stationary power applications. With the assistance of TR’s on-site production and supply equipment, creating hydrogen both via water electrolysis and steam reforming of natural gas, biogas or bioethanol, Loop will be able to provide more convenient and cost-effective hydrogen solutions

Moody's to Acquire RMS, Leader in Climate & Natural Disaster Risk5.8.2021 13:18:00 CEST | Press release

Moody's Corporation (NYSE: MCO) and RMS announced today that they have entered into a definitive agreement for Moody’s to acquire RMS, a leading global provider of climate and natural disaster risk modeling and analytics, for approximately $2.0 billion from Daily Mail and General Trust plc (LON: DMGT). The acquisition will immediately increase Moody’s insurance data and analytics business to nearly $500 million in revenue and will accelerate the development of the Company’s global integrated risk capabilities to address the next generation of risk assessment. With over 400 risk models covering 120 countries, RMS is the world’s leading provider of climate and natural disaster risk modeling serving the global property and casualty (P&C) insurance and reinsurance industries. For the fiscal year ending September 30, 2021, RMS is expected to generate revenue of approximately $320 million1 and adjusted operating income of approximately $55 million1. "Today’s leaders face a complex, interlink

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO ® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks5.8.2021 13:00:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the publication of the final results from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE) designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO® (lanadelumab) 300mg every two weeks for up to 2.5 years. The study results show that preventative treatment with TAKHZYRO markedly reduced the frequency of hereditary angioedema (HAE) attacks in patients 12 years of age and older who received treatment for a mean duration of almost 2.5 years (29.6 months; 8.2 standard deviation).1 The data were published online this month in the journal Allergy. Secondary endpoints of the study showed the mean (min;max) HAE attack rate observed in the study population (N=209) was reduced by 87.4 percent (-100; 852.8) overall versus baseline, and attacks requiring acute treatment (N=106) were reduced by 93.4 percent (-100; -52.8).1 Reductions were

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom